Page last updated: 2024-12-07
ro 24-5098
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
Ro 24-5098: structure given in first source; has anti-HIV activity [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
| ID Source | ID |
|---|---|
| PubMed CID | 124453 |
| CHEMBL ID | 421506 |
| SCHEMBL ID | 9679986 |
| MeSH ID | M0186169 |
Synonyms (16)
| Synonym |
|---|
| CHEMBL421506 |
| iso-dda |
| isodda |
| 127682-75-1 |
| [(2r,4r)-4-(6-aminopurin-9-yl)tetrahydrofuran-2-yl]methanol |
| l-threo-pentitol, 2-(6-amino-9h-purin-9-yl)-1,4-anhydro-2,3-dideoxy- |
| ro 24-5098 |
| [(2r,4r)-4-(6-aminopurin-9-yl)oxolan-2-yl]methanol |
| ro24-5098 |
| ro-24-5098 |
| SCHEMBL9679986 |
| (2r-cis)-4-(6-amino-9h-purin-9-yl)tetrahydro-2-furanmethanol |
| FJKGKWDFDNULCJ-RNFRBKRXSA-N |
| DTXSID40155624 |
| ((2r,4r)-4-(6-amino-9h-purin-9-yl)tetrahydrofuran-2-yl)methanol |
| AKOS040749330 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Bioassays (11)
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID31907 | In vitro effective dose which provides 50% protection of ATH-8 cells against the cytopathic effect of HIV; range 5-15 uM | 1992 | Journal of medicinal chemistry, Jun-26, Volume: 35, Issue:13 | Synthesis and anti-HIV activity of isonucleosides. |
| AID32074 | The compound was tested for anti HIV-activity (active) against ATH8 cell line | 1999 | Bioorganic & medicinal chemistry letters, Jul-19, Volume: 9, Issue:14 | Correlation of anti-HIV activity with structure: use of electrostatic potential and conformational analysis. |
| AID232356 | Ratio of CC50 value that of EC50 value(HIV-2) | 1994 | Journal of medicinal chemistry, Oct-14, Volume: 37, Issue:21 | Synthesis and evaluation of the anti-HIV activity of aza and deaza analogues of isoddA and their phosphates as prodrugs. |
| AID105158 | Effective concentration required to achieve 50% protection of MT-4 cells against cytopathic effect of HIV-1 (4 days) | 1994 | Journal of medicinal chemistry, Oct-14, Volume: 37, Issue:21 | Synthesis and evaluation of the anti-HIV activity of aza and deaza analogues of isoddA and their phosphates as prodrugs. |
| AID82727 | Concentration required to inhibit HIV replication by 50% | 1992 | Journal of medicinal chemistry, Jun-26, Volume: 35, Issue:13 | Synthesis and anti-HIV activity of isonucleosides. |
| AID82581 | The compound was tested for anti-HIV activity; Range = 5.0-15.0 uM | 1991 | Journal of medicinal chemistry, Sep, Volume: 34, Issue:9 | Synthesis and biological evaluation of 4-purinylpyrrolidine nucleosides. |
| AID106234 | The compound was tested for anti HIV-activity (active) against MT-4 cell line | 1999 | Bioorganic & medicinal chemistry letters, Jul-19, Volume: 9, Issue:14 | Correlation of anti-HIV activity with structure: use of electrostatic potential and conformational analysis. |
| AID104773 | Concentration required to reduce the viability of mock-infected MT-4 cells by 50% (4 days) | 1994 | Journal of medicinal chemistry, Oct-14, Volume: 37, Issue:21 | Synthesis and evaluation of the anti-HIV activity of aza and deaza analogues of isoddA and their phosphates as prodrugs. |
| AID31902 | In vitro cytotoxicity against uninfected ATH-8 (human T-cell) cell line. | 1992 | Journal of medicinal chemistry, Jun-26, Volume: 35, Issue:13 | Synthesis and anti-HIV activity of isonucleosides. |
| AID105159 | Effective concentration required to achieve 50% protection of MT-4 cells against cytopathic effect of HIV-2 (8 days) | 1994 | Journal of medicinal chemistry, Oct-14, Volume: 37, Issue:21 | Synthesis and evaluation of the anti-HIV activity of aza and deaza analogues of isoddA and their phosphates as prodrugs. |
| AID232355 | Ratio of CC50 value that of EC50 value(HIV-1) | 1994 | Journal of medicinal chemistry, Oct-14, Volume: 37, Issue:21 | Synthesis and evaluation of the anti-HIV activity of aza and deaza analogues of isoddA and their phosphates as prodrugs. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
Research
Studies (8)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 7 (87.50) | 18.2507 |
| 2000's | 1 (12.50) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
Market Indicators
Research Demand Index: 12.25
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.25) All Compounds (24.57) |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 1 (12.50%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 7 (87.50%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||